Abstract
Delivery of therapeutic agents from self-assembled monolayers (SAMs) on 316L stainless steel (SS) has been demonstrated as a viable method to deliver drugs for localized coronary artery stent application. SAMs are highlyordered, nano-sized molecular coatings, adding 1-10 nm thickness to a surface. Hydroxyl terminated alkanethiol SAMs of 11-mercapto-1-undecanol ( – OH SAM) were formed on 316L SS with 48 hr immersion in ethanolic solutions. Attachment of ibuprofen (a model drug) to the functional SAMs was carried out in toluene for 5 hrs at 60 C using Novozume-435 as a biocatalyst. SAM formation and subsequent attachment of ibuprofen was characterized collectively using X-ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FTIR), and contact angle (CA) measurements. The quantitative in vitro release of ibuprofen into a “physiological” buffer solution was characterized using reverse phase HPLC. Drug release kinetics showed that 14.1 μg of ibuprofen eluted over a period of 35 days with 2.7μg being eluted in the first day and the remaining being eluted over a period of 35 days. The drug release kinetics showed an increase in ibuprofen elution that occurred during first 14 days (2.7μg in 1 day to 9.5 μg in 14 days), following which there was a decrease in the rate of elution. Thus, functional SAMs on 316L SS could be used as tethers for drug attachment and could serve as a drug delivery mechanism from stainless steel implants such as coronary artery stents.
Keywords: Drug delivery, 316 L SS, stent, self assembled monolayers
Current Topics in Medicinal Chemistry
Title: Drug Delivery from Therapeutic Self-Assembled Monolayers (T-SAMs) on 316L Stainless Steel
Volume: 8 Issue: 4
Author(s): Dave M. Johnson, Anil Mahapatro, Devang N. Patel, Marc D. Feldman, Arturo A. Ayon and C. Mauli Agrawal
Affiliation:
Keywords: Drug delivery, 316 L SS, stent, self assembled monolayers
Abstract: Delivery of therapeutic agents from self-assembled monolayers (SAMs) on 316L stainless steel (SS) has been demonstrated as a viable method to deliver drugs for localized coronary artery stent application. SAMs are highlyordered, nano-sized molecular coatings, adding 1-10 nm thickness to a surface. Hydroxyl terminated alkanethiol SAMs of 11-mercapto-1-undecanol ( – OH SAM) were formed on 316L SS with 48 hr immersion in ethanolic solutions. Attachment of ibuprofen (a model drug) to the functional SAMs was carried out in toluene for 5 hrs at 60 C using Novozume-435 as a biocatalyst. SAM formation and subsequent attachment of ibuprofen was characterized collectively using X-ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FTIR), and contact angle (CA) measurements. The quantitative in vitro release of ibuprofen into a “physiological” buffer solution was characterized using reverse phase HPLC. Drug release kinetics showed that 14.1 μg of ibuprofen eluted over a period of 35 days with 2.7μg being eluted in the first day and the remaining being eluted over a period of 35 days. The drug release kinetics showed an increase in ibuprofen elution that occurred during first 14 days (2.7μg in 1 day to 9.5 μg in 14 days), following which there was a decrease in the rate of elution. Thus, functional SAMs on 316L SS could be used as tethers for drug attachment and could serve as a drug delivery mechanism from stainless steel implants such as coronary artery stents.
Export Options
About this article
Cite this article as:
Johnson M. Dave, Mahapatro Anil, Patel N. Devang, Feldman D. Marc, Ayon A. Arturo and Agrawal Mauli C., Drug Delivery from Therapeutic Self-Assembled Monolayers (T-SAMs) on 316L Stainless Steel, Current Topics in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/156802608783790929
DOI https://dx.doi.org/10.2174/156802608783790929 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Emerging Roles of Leptin and Ghrelin in Cardiovascular Physiology and Pathophysiology
Current Vascular Pharmacology The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19
Recent Patents on Anti-Infective Drug Discovery bmp3 is Required for Integrity of Blood Brain Barrier by Promoting Pericyte Coverage in Zebrafish Embryos
Current Molecular Medicine Meet Our Co-Editor
Current Vascular Pharmacology Overview of Current Trends and the Future of Thromboprophylaxis in Orthopaedic Surgery
Vascular Disease Prevention (Discontinued) Reviewed and updated Algorithm for Genetic Characterization of Syndromic Obesity Phenotypes
Current Genomics Prevalence and Clinical Profile of Undiagnosed Diabetes Mellitus: Data from a Tertiary Hospital
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research Left Ventricular Hypertrophy Beyond Hemodynamics: Genetic, Metabolic and Hormonal Factors
Current Hypertension Reviews The Therapeutic Potential of Microencapsulate Implants: Patents and Clinical Trials
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary)
Current Alzheimer Research Nanomedicine in the Diagnosis and Treatment of Atherosclerosis-A Systematic Review
Cardiovascular & Hematological Disorders-Drug Targets Targeting RSV with Vaccines and Small Molecule Drugs
Infectious Disorders - Drug Targets Low Radiation Dose with Triple-Rule-Out CT Angiography in Diagnosis of Acute Chest Pain
Current Medical Imaging Management of Retained Intervention Guide-wire: A Literature Review
Current Cardiology Reviews Transient Receptor Potential Channels, the Kidney and Hypertension
Current Hypertension Reviews Pre- and Post-conditioning in Cardiovascular Surgery
Current Vascular Pharmacology Surviving Sepsis Campaign: A Project to Change Sepsis Trajectory
Endocrine, Metabolic & Immune Disorders - Drug Targets Safe Utilization of Hyperglycemia Management in the ICU
Current Drug Safety Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design